Does Relacorilant Interact with Paclitaxel Aibumin Bound?
Relacorilant and Paclitaxel Aibumin Bound have a contraindicated drug interaction according to U.S. FDA drug labeling data. Avoid coadministration of relacorilant plus nab-paclitaxel with strong CYP3A inducers. Both are CYP3A substrates; inducers decrease concentrations and may reduce effectiveness. The mechanism involves cyp3a induction decreases relacorilant and paclitaxel concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Contraindicated
- Paclitaxel Aibumin Bound Class
- Microtubule Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Relacorilant and Paclitaxel Aibumin Bound occurs because cyp3a induction decreases relacorilant and paclitaxel concentrations. Clinically, this means avoid coadministration of relacorilant plus nab-paclitaxel with strong cyp3a inducers. both are cyp3a substrates; inducers decrease concentrations and may reduce effectiveness. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.
What To Tell Your Doctor or Pharmacist
If you are taking Relacorilant and your doctor is considering prescribing Paclitaxel Aibumin Bound (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider